Moberg Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Moberg Pharma has a total shareholder equity of SEK686.8M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK706.1M and SEK19.3M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 293.29m |
| Equity | SEK 686.82m |
| Total liabilities | SEK 19.27m |
| Total assets | SEK 706.09m |
Recent financial health updates
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Feb 12
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Sep 14Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Nov 16Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
Jan 17Recent updates
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Feb 12We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Sep 14Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 08Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Nov 16Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
Jan 17Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
Dec 03
Financial Position Analysis
Short Term Liabilities: MOB's short term assets (SEK300.1M) exceed its short term liabilities (SEK16.7M).
Long Term Liabilities: MOB's short term assets (SEK300.1M) exceed its long term liabilities (SEK2.5M).
Debt to Equity History and Analysis
Debt Level: MOB is debt free.
Reducing Debt: MOB has no debt compared to 5 years ago when its debt to equity ratio was 2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MOB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MOB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 23:14 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moberg Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |